Lucy Lu for STAT

When it’s time to save a limb, novel clinic meets unhoused people where they are 

Homeless people find salvation in an unusual clinic, created by Massachusetts General Hospital in Boston, that meets them where they are to treats things like peripheral artery disease.

By Elizabeth Cooney

STAT+ | Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association in New Orleans, on Saturday.

By Elaine Chen

STAT+ | J&J spends $1 billion to enter KRAS race for cancer treatments

Johnson & Johnson's acquisition of the startup, Firefly Bio, follows the release of field-changing data from Revolution Medicines.

By Jason Mast

David McNew/Getty Images

Opinion: American horses are obese, too

Obese horses aren’t lazy or making poor choices. They’re victims of a food system — just like humans.

By Joshua Moen

STAT+ | Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

The two drugs, vopimetostat from Tango Therapeutics and daraxonrasib from Revolution Medicines, will now be tested in a Phase 3 trial.

By Andrew Joseph

STAT+ | New data may cast doubt on competitiveness of Boehringer’s obesity drug

Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss compared to other drugs on the market.

By Elaine Chen

Jospin Mwisha / AFP via Getty Images

Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action

Stopping Ebola, 'an unforgiving enemy,' will require a massive, immediate, and meticulous response, writes former CDC Director Tom Frieden.

By Tom Frieden

Opinion: $2 million gene therapy cures require a financing model

Health care needs a financing model to pay for $2 million curative therapies that deliver decades of value with a single intervention.

By William V. Padula